Publication | Closed Access

Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial

Breast OncologyOncologyMaintenance CapecitabineInitial First-line BevacizumabBreast CancerPharmacotherapyCancer TreatmentMedicineRadiation OncologyBevacizumab Versus Bevacizumab